Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio® for the Treatment of Gastric Cancer Poster presented at ASCO GI
* Results showed partial response being confirmed in 7 out of 42 patients * Partial response was observed in 3 out of 8 patients who were previously treated by immunotherapy SEOUL, South Korea, Jan. 24, 2024 /PRNewswire/ -- Genome & Company (KOSDAQ: 314130), a clinical stage biotech leading in...
Positive Results from Interim Analysis of 'GEN-001' Plus avelumab (Bavencio®) Phase II Trial
* Positive primary endpoint result of objective response rate (ORR) from the planned interim analysis of Phase II trial in advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJ). * Top-line data of the final analysis from Phase II to be announced in the second half of next year. S...
Positive Results from Interim Analysis of 'GEN-001' Plus avelumab (Bavencio®) Phase II Trial
SEOUL, South Korea, May 19, 2023 /PRNewswire/ -- Genome & Company (CEO: Pae, Jisoo), a global leading microbiome therapeutics developer, announced that this phase II trial (NCT05419362) will continue without modifications to move on to the second stage, based on the positive result of the interim...
